Clinical Mass Spectrometry Approaches to Myeloma and Amyloidosis

David L Murray; Surendra Dasari

doi:10.1016/j.cll.2021.03.003

Clinical Mass Spectrometry Approaches to Myeloma and Amyloidosis

Clin Lab Med. 2021 Jun;41(2):203-219. doi: 10.1016/j.cll.2021.03.003. Epub 2021 Apr 24.

Authors

David L Murray¹, Surendra Dasari²

Affiliations

¹ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: murray.david@mayo.edu.
² Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

PMID: 34020760
DOI: 10.1016/j.cll.2021.03.003

Abstract

The diagnosis of myeloma and other plasma cell disorders has traditionally been done with the aid of electrophoretic methods, whereas amyloidosis has been characterized by immunohistochemistry. Mass spectrometry has recently been established as an alternative to these traditional methods and has been proved to bring added benefit for patient care. These newer mass spectrometry-based methods highlight some of the key advantages of modern proteomic methods and how they can be applied to the routine care of patients.

Keywords: Amyloidosis; Clinical mass spectrometry; MALDI-TOF mass spectrometry; Multiple myeloma; Plasma cell disorders; Proteomics.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Amyloidosis* / diagnosis
Humans
Mass Spectrometry
Multiple Myeloma* / diagnosis
Paraproteinemias*
Proteomics
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization